Additional file 1 of Assessing the safety of lipid-modifying medications among Chinese adolescents: a drug-target Mendelian randomization study

Additional file 1. Table S1. The primary efficacy outcomes from the “Children of 1997” birth cohort. Table S2. The safety outcomes from the “Children of 1997” birth cohort. Table S3. The genetic variants selected for the HMGCR score and PCSK9 score and their association in the Global Lipids Genetics Consortium and the “Children of 1997” birth cohort. Table S4. The effect of genetic inhibition of HMGCR and PCSK9 on coronary artery disease in East Asian. Table S5. The effect of genetic inhibition of HMGCR and PCSK9 on efficacy outcomes in the “Children of 1997” birth cohort. Table S6. The effect of genetic inhibition of HMGCR and PCSK9 on efficacy outcomes using complete case analysis in the “Children of 1997” birth cohort. Table S7. The effect of genetic inhibition of HMGCR and PCSK9 (using index variant) on efficacy outcomes in the “Children of 1997” birth cohort. Table S8. The effect of genetic inhibition of HMGCR and PCSK9 on safety outcomes in the “Children of 1997” birth cohort. Table S9. The effect of genetic inhibition of HMGCR and PCSK9 on safety outcomes using complete case analysis in the “Children of 1997” birth cohort. Table S10. The effect of genetic inhibition of HMGCR and PCSK9 (using index variant) on safety outcomes in the “Children of 1997” birth cohort. Supplementary Note. R code for Mendelian randomization analysis, principal component analysis, and visualization.